Regenerative medicine company LifeNet Health revealed on Wednesday that it has completed the first of three phases of its state-of-the-art Virginia Beach processing facility, which strengthens its operational and logistical capabilities.
Under the first phase of the project, the company has consolidated the logistics associated with providing technologically advanced bone grafts as well as cardiac and vascular grafts, which are used to repair life-threatening heart and circulatory system defects.
A supporting facility since 2001, the investment in the company's satellite location on Bayside Road, near Norfolk International Airport, will make it the largest of the four tissue graft-processing facilities once all phases are complete. In total, it represents half of the more than USD12m dedicated to facilities in Virginia since 2017.
In addition, the company has hired more than 200 people for highly skilled, technical jobs in Virginia under the phase one of the project.
By April 2021, the Bayside facility will include 20 Class 10,000 clean rooms, specialised suites designed to ensure the safety of the grafts as well as to prepare and store critically needed tissues.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA